Analytical Data
-
Gene name
SCGB1A1
- Application
-
Alternative Names
SCGB1A1；KIAA1174；LIMR；Protein LMBR1L
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P11684
-
Expression Region
20-91aa
-
AA Sequence
MKHHHHHHAS EICPSFQRVI ETLLMDTPSS YEAAMELFSP DQDMREAGAQ LKKLVDTLPQ KPRESIIKLM EKIAQSSLCN
-
Molecular Weight
9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SCGB1A1, also known as Secretoglobin family 1A member 1 or Clara cell protein (CC10), is a secreted glycoprotein primarily expressed in the epithelial cells of the lung and involved in various biological functions, including anti-inflammatory responses and surfactant metabolism. Research into SCGB1A1 is significant due to its potential role in respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis. Abnormal expression levels of SCGB1A1 have been linked to airway inflammation and remodeling, making it a candidate for understanding the molecular mechanisms of these conditions. Additionally, SCGB1A1 has been studied for its potential as a biomarker for lung disease and its implications in lung cancer pathogenesis. The generation of recombinant SCGB1A1 proteins allows for detailed characterization of its structure and function, paving the way for new therapeutic strategies. By employing techniques such as protein expression systems and purification methods, researchers can obtain sufficient quantities of this protein for in-depth study, which enhances our understanding of its biological roles and its potential applications in clinical settings. Overall, the exploration of SCGB1A1 as a recombinant protein is essential for advancing our knowledge of pulmonary biology and developing targeted therapies for respiratory ailments.
